Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas-related GPCRs and unexpected new pathways need to be also explored. Read full article

autophagy deficiency in myeloid cells "Background Eosinophilic inflammation is a hallmark of refractory chronic

captured an increasing amount of attention because of its involvement in various diseases, such as idiopathic been approved by the FDA thus far, at least three antagonists have entered phase Ⅱ clinical trials for idiopathic 18F-BMS-986327) has entered phase Ⅰ clinical trials for positron emission tomography (PET) imaging of idiopathic

expiratory volume, airflow obstruction and increased mucus production in asthma; loss of sense of smell in chronic Further research is needed to better understand the neuroimmune mechanisms that underlie chronic, sustained ligand 17 , CCL17 , CGRP , CIU , COPD , CRSsNP , CRSwNP , CSF2 , CSU , Calcitonin gene-related peptide , Chronic idiopathic urticaria , Chronic obstructive pulmonary disease , Chronic rhinosinusitis with nasal polyps , Chronic rhinosinusitis without nasal polyps , Chronic spontaneous urticaria , Colony stimulating factor

protein-coupled receptor (GPCR) and plays important roles in various inflammatory diseases and cancers, including chronic Yishi Xie , Wenbin Kuang , Dawei Wang , Kai Yuan , Peng Yang Tags CXCR2 , CXCR2 antagonist , Cancer , Chronic

governs macrophage migration during tissue inflammation Published date December 12, 2023 Abstract "Chronic Macrophages are continuously recruited to tissues during chronic inflammation where they exacerbate or